191 related articles for article (PubMed ID: 30819907)
1. p66Shc deficiency in the Eμ-TCL1 mouse model of chronic lymphocytic leukemia enhances leukemogenesis by altering the chemokine receptor landscape.
Patrussi L; Capitani N; Ulivieri C; Manganaro N; Granai M; Cattaneo F; Kabanova A; Mundo L; Gobessi S; Frezzato F; Visentin A; Finetti F; Pelicci PG; D'Elios MM; Trentin L; Semenzato G; Leoncini L; Efremov DG; Baldari CT
Haematologica; 2019 Oct; 104(10):2040-2052. PubMed ID: 30819907
[TBL] [Abstract][Full Text] [Related]
2. A novel class of oxazepine-based anti-cancer agents induces cell death in primary human CLL cells and efficiently reduces tumor growth in Eμ-TCL1 mice through the JNK/STAT4/p66Shc axis.
Vanni F; Lopresti L; Zurli V; Kabanova A; Cattaneo F; Sicuranza A; Gozzetti A; Gemma S; Zisterer DM; Bocchia M; Campiani G; Baldari CT; Butini S; Ulivieri C
Pharmacol Res; 2021 Dec; 174():105965. PubMed ID: 34732370
[TBL] [Abstract][Full Text] [Related]
3. Par-4 overexpression impedes leukemogenesis in the Eµ-TCL1 leukemia model through downregulation of NF-κB signaling.
Greene JT; Mani R; Ramaswamy R; Frissora F; Yano M; Zapolnik K; Harrington B; Wasmuth R; Tran M; Mo X; McKenna M; Rangnekar VM; Byrd JC; Bondada S; Muthusamy N
Blood Adv; 2019 Apr; 3(8):1255-1266. PubMed ID: 30987970
[TBL] [Abstract][Full Text] [Related]
4. Impaired expression of p66Shc, a novel regulator of B-cell survival, in chronic lymphocytic leukemia.
Capitani N; Lucherini OM; Sozzi E; Ferro M; Giommoni N; Finetti F; De Falco G; Cencini E; Raspadori D; Pelicci PG; Lauria F; Forconi F; Baldari CT
Blood; 2010 May; 115(18):3726-36. PubMed ID: 20061561
[TBL] [Abstract][Full Text] [Related]
5. P66Shc: A Pleiotropic Regulator of B Cell Trafficking and a Gatekeeper in Chronic Lymphocytic Leukemia.
Patrussi L; Capitani N; Baldari CT
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32325830
[TBL] [Abstract][Full Text] [Related]
6. p66Shc deficiency enhances CXCR4 and CCR7 recycling in CLL B cells by facilitating their dephosphorylation-dependent release from β-arrestin at early endosomes.
Patrussi L; Capitani N; Cattaneo F; Manganaro N; Gamberucci A; Frezzato F; Martini V; Visentin A; Pelicci PG; D'Elios MM; Trentin L; Semenzato G; Baldari CT
Oncogene; 2018 Mar; 37(11):1534-1550. PubMed ID: 29326436
[TBL] [Abstract][Full Text] [Related]
7. Expression of the p66Shc protein adaptor is regulated by the activator of transcription STAT4 in normal and chronic lymphocytic leukemia B cells.
Cattaneo F; Patrussi L; Capitani N; Frezzato F; D'Elios MM; Trentin L; Semenzato G; Baldari CT
Oncotarget; 2016 Aug; 7(35):57086-57098. PubMed ID: 27494881
[TBL] [Abstract][Full Text] [Related]
8. Leukemic cell-secreted interleukin-9 suppresses cytotoxic T cell-mediated killing in chronic lymphocytic leukemia.
Boncompagni G; Tatangelo V; Lopresti L; Ulivieri C; Capitani N; Tangredi C; Finetti F; Marotta G; Frezzato F; Visentin A; Ciofini S; Gozzetti A; Bocchia M; Calzada-Fraile D; Martin Cofreces NB; Trentin L; Patrussi L; Baldari CT
Cell Death Dis; 2024 Feb; 15(2):144. PubMed ID: 38360867
[TBL] [Abstract][Full Text] [Related]
9. Enhanced IL-9 secretion by p66Shc-deficient CLL cells modulates the chemokine landscape of the stromal microenvironment.
Patrussi L; Manganaro N; Capitani N; Ulivieri C; Tatangelo V; Libonati F; Finetti F; Frezzato F; Visentin A; D'Elios MM; Trentin L; Semenzato G; Baldari CT
Blood; 2021 Apr; 137(16):2182-2195. PubMed ID: 33181836
[TBL] [Abstract][Full Text] [Related]
10. ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice.
Widhopf GF; Cui B; Ghia EM; Chen L; Messer K; Shen Z; Briggs SP; Croce CM; Kipps TJ
Proc Natl Acad Sci U S A; 2014 Jan; 111(2):793-8. PubMed ID: 24379361
[TBL] [Abstract][Full Text] [Related]
11. Delayed development of chronic lymphocytic leukemia in the absence of macrophage migration inhibitory factor.
Reinart N; Nguyen PH; Boucas J; Rosen N; Kvasnicka HM; Heukamp L; Rudolph C; Ristovska V; Velmans T; Mueller C; Reiners KS; von Strandmann EP; Krause G; Montesinos-Rongen M; Schlegelberger B; Herling M; Hallek M; Fingerle-Rowson G
Blood; 2013 Jan; 121(5):812-21. PubMed ID: 23118218
[TBL] [Abstract][Full Text] [Related]
12. Absence of caveolin-1 leads to delayed development of chronic lymphocytic leukemia in Eμ-TCL1 mouse model.
Shukla A; Cutucache CE; Sutton GL; Pitner MA; Rai K; Rai S; Opavsky R; Swanson PC; Joshi SS
Exp Hematol; 2016 Jan; 44(1):30-7.e1. PubMed ID: 26435347
[TBL] [Abstract][Full Text] [Related]
13. CD74 is dispensable for development of chronic lymphocytic leukemia in
Barthel R; Fedorchenko O; Velmans T; Rosen N; Nguyen PH; Reinart N; Florin A; Herling M; Hallek M; Fingerle-Rowson G
Leuk Lymphoma; 2020 Dec; 61(12):2799-2810. PubMed ID: 32667245
[TBL] [Abstract][Full Text] [Related]
14. A novel potent class I HDAC inhibitor reverses the STAT4/p66Shc apoptotic defect in B cells from chronic lymphocytic leukemia patients.
Rossi S; Tatangelo V; Dichiara M; Butini S; Gemma S; Brogi S; Pasquini S; Cappello M; Vincenzi F; Varani K; Lopresti L; Malchiodi M; Carrara C; Gozzetti A; Bocchia M; Marotta G; Patrussi L; Carullo G; Baldari CT; Campiani G
Biomed Pharmacother; 2024 May; 174():116537. PubMed ID: 38579402
[TBL] [Abstract][Full Text] [Related]
15. S1P1 expression is controlled by the pro-oxidant activity of p66Shc and is impaired in B-CLL patients with unfavorable prognosis.
Capitani N; Patrussi L; Trentin L; Lucherini OM; Cannizzaro E; Migliaccio E; Frezzato F; Gattazzo C; Forconi F; Pelicci P; Semenzato G; Baldari CT
Blood; 2012 Nov; 120(22):4391-9. PubMed ID: 23033271
[TBL] [Abstract][Full Text] [Related]
16. Chronic lymphocytic leukemia of Emu-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression.
Enzler T; Kater AP; Zhang W; Widhopf GF; Chuang HY; Lee J; Avery E; Croce CM; Karin M; Kipps TJ
Blood; 2009 Nov; 114(20):4469-76. PubMed ID: 19755673
[TBL] [Abstract][Full Text] [Related]
17. NF-κB p50 (
Chen TL; Tran M; Lakshmanan A; Harrington BK; Gupta N; Goettl VM; Lehman AM; Trudeau S; Lucas DM; Johnson AJ; Byrd JC; Hertlein E
Blood; 2017 Jul; 130(3):376-379. PubMed ID: 28515090
[No Abstract] [Full Text] [Related]
18. Accelerated progression of chronic lymphocytic leukemia in Eμ-TCL1 mice expressing catalytically inactive RAG1.
Nganga VK; Palmer VL; Naushad H; Kassmeier MD; Anderson DK; Perry GA; Schabla NM; Swanson PC
Blood; 2013 May; 121(19):3855-66, S1-16. PubMed ID: 23502221
[TBL] [Abstract][Full Text] [Related]
19. Secretory IgM Exacerbates Tumor Progression by Inducing Accumulations of MDSCs in Mice.
Tang CH; Chang S; Hashimoto A; Chen YJ; Kang CW; Mato AR; Del Valle JR; Gabrilovich DI; Hu CC
Cancer Immunol Res; 2018 Jun; 6(6):696-710. PubMed ID: 29650518
[TBL] [Abstract][Full Text] [Related]
20. Chronic lymphocytic leukemia disease progression is accelerated by APRIL-TACI interaction in the TCL1 transgenic mouse model.
Lascano V; Guadagnoli M; Schot JG; Luijks DM; Guikema JE; Cameron K; Hahne M; Pals S; Slinger E; Kipps TJ; van Oers MH; Eldering E; Medema JP; Kater AP
Blood; 2013 Dec; 122(24):3960-3. PubMed ID: 24100449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
